A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients
about
Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapyNew agents for the treatment of hepatitis C in patients co-infected with HIVHepatitis C and HIV co-infection: new drugs in practice and in the pipelineReliability and extension of quantitative prediction of CYP3A4-mediated drug interactions based on clinical dataPros and cons of liver transplantation in human immunodeficiency virus infected recipients.Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.HIV and liver transplantation: The British Columbia experience, 2004 to 2013.Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravirHIV-1, HCV and alcohol in the CNS: potential interactions and effects on neuroinflammation.Development of NanoART for HIV Treatment: Minding the Cytochrome P450 (CYP) EnzymesCurrent management of hepatitis C virus infection in patients with HIV co-infectionDrug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and TreatmentCIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults.NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety.New treatments for chronic hepatitis C: an overview for paediatricians.Treatment of chronic hepatitis C in patients with HIV/HCV coinfectionClinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C.Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese.
P2860
Q26771182-190AD311-87AF-467E-BE97-17B45CFA647AQ27006027-D39AC4D0-CD14-48B0-A7C5-CFE07DC85451Q27022596-605170BB-974A-4A34-A761-2B8162934B40Q30856965-4C75A933-7386-4F7A-A770-1292F6131085Q33594879-20421CA8-0AD2-4F68-81B9-2DF30093F62EQ34143327-339EBCC2-4524-44ED-90E0-2A3235FB1FE8Q34238552-7B212804-9624-4C93-95B1-888118ABCEF9Q34570900-9CC072FB-7AAD-4E53-8221-89C250F45327Q35596364-AB8BF9A3-E2CF-405C-B77B-811C3122F483Q36338109-56B6E36C-E42D-43B8-AC07-5D9B22E8CD32Q36590774-57D8C11D-A51D-4565-A37F-222344423148Q36668891-EB997012-4572-477A-B5D0-ACCC714775BAQ37100669-0403536E-09D1-4964-AFB1-026668EC1A1AQ37525649-081A8AC2-3811-4369-A2D9-1A85F02291CCQ38215505-433599C0-2348-41D6-BA12-DEEE0952450DQ38282842-4905A54D-1881-4919-929E-146B0D3A3D78Q38352572-008EFBC0-196D-4E30-B13C-9881183F862DQ47108259-F76F6482-D9F3-42F8-AB8F-1D9C30BEEE4DQ55164145-1D9C160E-7786-47D8-94F3-A8970E2D6923
P2860
A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A review of drug interactions ...... or HIV and transplant patients
@ast
A review of drug interactions ...... or HIV and transplant patients
@en
A review of drug interactions ...... or HIV and transplant patients
@nl
type
label
A review of drug interactions ...... or HIV and transplant patients
@ast
A review of drug interactions ...... or HIV and transplant patients
@en
A review of drug interactions ...... or HIV and transplant patients
@nl
prefLabel
A review of drug interactions ...... or HIV and transplant patients
@ast
A review of drug interactions ...... or HIV and transplant patients
@en
A review of drug interactions ...... or HIV and transplant patients
@nl
P2093
P3181
P1476
A review of drug interactions ...... or HIV and transplant patients
@en
P2093
P304
P3181
P407
P577
2012-01-01T00:00:00Z